MRI for monitoring response to preventive treatment in multiple sclerosis

References

• The IFN β Study Group. Interferon β-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFN β Multiple Sclerosis Study Group. Neurology43, 655–661 (1993).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol.39, 285–294 (1996).
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) study group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet352, 1498–1504 (1998).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology45, 1268–1276 (1995).
   PubMed Web of Science ®Google Scholar
• Trojano M, Pellegrini F, Fuiani A et al. New natural history of interferon-β-treated relapsing multiple sclerosis. Ann. Neurol.61, 300–306 (2007).
   PubMed Web of Science ®Google Scholar
• Hartung HP, Gonsette R, König N et al. Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet360, 2018–2025 (2002).
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.354, 899–910 (2006).
   PubMed Web of Science ®Google Scholar
• Gasperini C, Ausili Cefaro L, Borriello G et al. Emerging oral drugs for multiple sclerosis. Expert Opin. Emerg. Drugs13, 465–477 (2008).
   PubMed Web of Science ®Google Scholar
• Rio J, Nos C, Tintoré M et al. Defining the response to interferon β in relapsing–remitting multiple sclerosis patients. Ann. Neurol.59, 344–352 (2006).
   PubMed Web of Science ®Google Scholar
• Portaccio E, Zipoli V, Siracusa G et al. Response to interferon-β therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. Mult. Scler.12, 281–286 (2006).
   PubMed Web of Science ®Google Scholar
• Trojano M, Liguori M, Paolicelli D et al. Interferon β in relapsing-remitting multiple sclerosis: an independent post-marketing study in southern Italy. Mult. Scler.9, 451–457 (2003).
   PubMed Web of Science ®Google Scholar
• Waubant E, Vukusic S, Gignoux L et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology61, 184–189 (2003).
   PubMed Web of Science ®Google Scholar
• O’Rourke K, Walsh C, Antonelli G et al. Predicting β-interferon failure in relapsing–remitting multiple sclerosis. Mult. Scler.13, 336–342 (2007).
   PubMed Web of Science ®Google Scholar
• Koudriavtseva T, Pozzilli C, Fiorelli M et al. Determinants of Gd-enhanced MRI response to IFN β-1a treatment in relapsing-remitting multiple sclerosis. Mult. Scler.4, 403–407 (1998).
   PubMedGoogle Scholar
• Tomassini V, Paolillo A, Russo P et al. Predictors of long-term clinical response to interferon β therapy in relapsing multiple sclerosis. J. Neurol.253, 287–293 (2006).
   PubMed Web of Science ®Google Scholar
• Rudick R, Lee J, Simon J. Defining interferon β response status in multiple sclerosis patients. Ann. Neurol.56, 548–555 (2004).
   PubMed Web of Science ®Google Scholar
• Durelli L, Berbero P, Bergui M et al. MRI activity and neutralizing antibody as predictor of response to IFNB treatment in MS. J. Neurol. Neurosurg. Psychiatry79, 646–651 (2008).
   PubMed Web of Science ®Google Scholar
• Rio J, Rovira A, Tintoré M et al. Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients. Mult. Scler.14, 479–484 (2008).
   PubMed Web of Science ®Google Scholar
• Miller DH, Albert PS, Barkhof F et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann. Neurol.39, 6–16 (1996).
   PubMed Web of Science ®Google Scholar
• Traboulsee A. MRI relapses have significant pathologic and clinical implications in multiple sclerosis. J. Neurol. Sci.256, 19–22 (2007).
   Google Scholar
• Yong VW. Differential mechanisms of action of interferon-β and glatiramer acetate in MS. Neurology59, 802–808 (2002).
   PubMed Web of Science ®Google Scholar
• Barkhof F, Filippi M, Miller DH et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain120, 2059–2069 (1997).
   PubMed Web of Science ®Google Scholar
• Koudriavtseva T, Thompson AJ, Fiorelli M et al. Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry62, 285–287 (1997).
   PubMed Web of Science ®Google Scholar
• Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med.346, 158–64 (2002).
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group and UBC MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon β-1a in relapsing MS. Neurology56, 1628–36 (2001).
   PubMed Web of Science ®Google Scholar